Loss of Lipocalin2 Confers Cisplatin Vulnerability Through Modulating NF-ĸB Mediated Ferroptosis Via Ferroportin

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2024 Jun 11

PMID 38859845

Authors

Meibao Feng

Xuesong Wu

Jing Zhang

Pei Chen

Senmi Qian

Chengdong Chang

Affiliations

Soon will be listed here.

Abstract

Cisplatin is a widely used anti-cancer drug. Unfortunately, many cancers often develop resistance, which contributes to tumor recurrence and poorly prognosis. Growing knowledge has suggested the therapeutic potential of ferroptosis in cancer. Lipocalin2 (LCN2) is demonstrated to be a critical iron metabolic factor and implies in ferroptosis. Here, we aim to explore its role in chemotherapy resistance. The influence of LCN2 on colorectal cancer (CRC) cell chemoresistance and ferroptosis were evaluated by in vitro and in vivo approaches. The interaction between LCN2, NF-ĸB and ferroportin (FPN) was assessed by western blots, immunohistochemistry and dual luciferase reporter assays. Results showed that LCN2 was highly expressed in tumor regression grade 1 (TRG1) cases than that in TRG3 specimens. Loss of LCN2 contributed to resistance to cisplatin-induced ferroptosis. Mechanistically, loss of LCN2 inhibited cisplatin sensitivity and cisplatin-induced ferroptosis through elevating FPN expression which was regulated by NF-ĸB, subsequently reducing Fe mediated Fenton reaction. Furthermore, FPN expression rate was much lower in TRG1 cases, and negative correlation between LCN2 and FPN expression was observed in clinical specimens. Collectively, low LCN2 expression enhances insensitivity of cisplatin to CRC cells via Fenton reaction mediated ferroptosis. LCN2/NF-ĸB/FPN pathway might be potentially utilized for chemoresistance strategy. LCN2 and FPN expression might be a promising biomarker of chemotherapy effect for CRC patients.

References

Valashedi M, Roushandeh A, Tomita K, Kuwahara Y, Pourmohammadi-Bejarpasi Z, Safarzadeh Kozani P . CRISPR/Cas9-mediated knockout of Lcn2 in human breast cancer cell line MDA-MB-231 ameliorates erastin-mediated ferroptosis and increases cisplatin vulnerability. Life Sci. 2022; 304:120704. DOI: 10.1016/j.lfs.2022.120704. View

Gupta U, Ghosh S, Wallace C, Shang P, Xin Y, Nair A . Increased LCN2 (lipocalin 2) in the RPE decreases autophagy and activates inflammasome-ferroptosis processes in a mouse model of dry AMD. Autophagy. 2022; 19(1):92-111. PMC: 9809950. DOI: 10.1080/15548627.2022.2062887. View

Rogler G . Chronic ulcerative colitis and colorectal cancer. Cancer Lett. 2013; 345(2):235-41. DOI: 10.1016/j.canlet.2013.07.032. View

Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P . Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol. 2004; 24(3):307-15. DOI: 10.1159/000078452. View

Halabian R, Roudkenar M, Jahanian-Najafabadi A, Hosseini K, Tehrani H . Co-culture of bone marrow-derived mesenchymal stem cells overexpressing lipocalin 2 with HK-2 and HEK293 cells protects the kidney cells against cisplatin-induced injury. Cell Biol Int. 2014; 39(2):152-63. DOI: 10.1002/cbin.10344. View

Yang W, Stockwell B . Ferroptosis: Death by Lipid Peroxidation. Trends Cell Biol. 2015; 26(3):165-176. PMC: 4764384. DOI: 10.1016/j.tcb.2015.10.014. View

Li S, He Y, Chen K, Sun J, Zhang L, He Y . RSL3 Drives Ferroptosis through NF-B Pathway Activation and GPX4 Depletion in Glioblastoma. Oxid Med Cell Longev. 2022; 2021:2915019. PMC: 8720588. DOI: 10.1155/2021/2915019. View

Ben-Neriah Y, Karin M . Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol. 2011; 12(8):715-23. DOI: 10.1038/ni.2060. View

Wang D, Lippard S . Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005; 4(4):307-20. DOI: 10.1038/nrd1691. View

10.

Yashiro M . Ulcerative colitis-associated colorectal cancer. World J Gastroenterol. 2014; 20(44):16389-97. PMC: 4248182. DOI: 10.3748/wjg.v20.i44.16389. View

11.

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

12.

Feng M, Feng J, Chen W, Wang W, Wu X, Zhang J . Lipocalin2 suppresses metastasis of colorectal cancer by attenuating NF-κB-dependent activation of snail and epithelial mesenchymal transition. Mol Cancer. 2016; 15(1):77. PMC: 5135816. DOI: 10.1186/s12943-016-0564-9. View

13.

Luo L, Deng L, Chen Y, Ding R, Li X . Identification of Lipocalin 2 as a Ferroptosis-Related Key Gene Associated with Hypoxic-Ischemic Brain Damage via STAT3/NF-κB Signaling Pathway. Antioxidants (Basel). 2023; 12(1). PMC: 9854551. DOI: 10.3390/antiox12010186. View

14.

Gao J, Luo T, Wang J . Gene interfered-ferroptosis therapy for cancers. Nat Commun. 2021; 12(1):5311. PMC: 8423858. DOI: 10.1038/s41467-021-25632-1. View

15.

Xie R, Cheng L, Huang M, Huang L, Chen Z, Zhang Q . NAT10 Drives Cisplatin Chemoresistance by Enhancing ac4C-Associated DNA Repair in Bladder Cancer. Cancer Res. 2023; 83(10):1666-1683. DOI: 10.1158/0008-5472.CAN-22-2233. View

16.

Wang D, Li X, Jiao D, Cai Y, Qian L, Shen Y . LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia. J Hematol Oncol. 2023; 16(1):30. PMC: 10044814. DOI: 10.1186/s13045-023-01429-1. View

17.

Deng L, He S, Li Y, Ding R, Li X, Guo N . Identification of Lipocalin 2 as a Potential Ferroptosis-related Gene in Ulcerative Colitis. Inflamm Bowel Dis. 2023; 29(9):1446-1457. DOI: 10.1093/ibd/izad050. View

18.

Wang S, Chen Z, Zhu S, Lu H, Peng D, Soutto M . PRDX2 protects against oxidative stress induced by H. pylori and promotes resistance to cisplatin in gastric cancer. Redox Biol. 2019; 28:101319. PMC: 6811995. DOI: 10.1016/j.redox.2019.101319. View

19.

Stockwell B, Jiang X, Gu W . Emerging Mechanisms and Disease Relevance of Ferroptosis. Trends Cell Biol. 2020; 30(6):478-490. PMC: 7230071. DOI: 10.1016/j.tcb.2020.02.009. View

20.

Min Y, Mao C, Chen S, Ma G, Wang J, Liu Y . Combating the drug resistance of cisplatin using a platinum prodrug based delivery system. Angew Chem Int Ed Engl. 2012; 51(27):6742-7. DOI: 10.1002/anie.201201562. View